专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明申请

US20170081404A1 NEW BISPECIFIC FORMAT SUITABLE FOR USE IN HIGH-THROUGH-PUT SCREENING 审中-公开
公开(公告)号：US20170081404A1
公开(公告)日：2017-03-23
申请号：US15311198
申请日：2015-05-28
申请人： UCB BIOPHARMA SPRL
发明人： HELENE MARGARET FINNEY , STEPHEN EDWARD RAPECKI , MICHAEL JOHN WRIGHT
IPC分类号： C07K16/28 , G01N33/68
CPC分类号： C07K16/28 , C07K16/00 , C07K16/14 , C07K16/468 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2319/00 , G01N33/6854
摘要： The present disclosure relates to a novel bispecific protein complex and a method of using the complexes to screen for synergistic or novel biological function. The bispecific format is particularly suitable for high-throughput screening because all of its components can be expressed from cells as individual units and the units can be assembled simply by mixing without employing conjugation or coupling chemistry.

82. 发明授权

US09597386B2 Outer membrane proteins of Histophilus somni and methods thereof 有权
公开(公告)号：US09597386B2
公开(公告)日：2017-03-21
申请号：US13796653
申请日：2013-03-12
申请人： Brice Dean Lilly , Jeffrey P. Knittel
发明人： Brice Dean Lilly , Jeffrey P. Knittel
IPC分类号： A61K39/02 , A61K39/102 , A61K39/00 , G01N33/68 , G01N33/569 , C07K14/285
CPC分类号： A61K39/102 , A61K2039/552 , C07K14/285 , G01N33/56911 , G01N33/6854 , G01N2333/285
摘要： The present invention relates to immunological compositions of outer membrane proteins (OMPs) of H. somni, as well as methods of extraction, a respiratory challenge model, methods of administration and diagnostic assays and kits.

83. 发明申请

US20170073414A1 Anti SIRP-alpha Antibodies and Bi-specific Macrophage Enhancing Antibodies 审中-公开
标题翻译：抗SIRP-α抗体和双特异性巨噬细胞增强抗体
公开(公告)号：US20170073414A1
公开(公告)日：2017-03-16
申请号：US15122560
申请日：2015-03-11
申请人： THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
发明人： Kipp Andrew Weiskopf , Aaron Michael Ring , Jens-Peter Volkmer , Irving L. Weissman , Nan Guo Ring
IPC分类号： C07K16/28 , G01N33/577 , G01N33/68 , A61K51/10 , C07K16/32
CPC分类号： C07K16/2803 , A61K51/1027 , A61K2039/505 , A61K2039/507 , C07K16/2863 , C07K16/2875 , C07K16/2887 , C07K16/32 , C07K2317/24 , C07K2317/31 , C07K2317/51 , C07K2317/515 , C07K2317/565 , C07K2317/64 , C07K2317/732 , C07K2317/76 , C07K2317/92 , G01N33/577 , G01N33/6854 , G01N2333/70503
摘要： Anti-SIRPα antibodies, including multi-specific anti-SIRPα antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRPα and can block the interaction of CD47 on one cell with SIRPα on a phagocytic cell. Antibodies that are bispecific for SIRPα and a second antigen are termed Bi-specific Macrophage Enhancing (BiME) antibodies and have emergent properties. The subject anti-SIRPα antibodies find use in various therapeutic methods. Embodiments of the disclosure include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRPα antibodies; and cell lines that produce the antibodies. Also provided are amino acid sequences of exemplary anti-SIRPα antibodies.
摘要翻译：提供抗SIRPα抗体，包括多特异性抗SIRPα抗体，以及相关组合物和方法。本公开的抗体结合SIRPα并且可以阻断一个细胞上的CD47与吞噬细胞上的SIRPα的相互作用。针对SIRPα和第二抗原双特异性的抗体称为Bi特异性巨噬细胞增殖（BiME）抗体，具有突发性。受试者抗SIRPα抗体可用于各种治疗方法。本公开的实施方案包括分离的抗体及其衍生物和片段，包含一种或多种抗SIRPα抗体的药物制剂; 和产生抗体的细胞系。还提供了示例性抗SIRPα抗体的氨基酸序列。

84. 发明授权

US09593162B2 Internalizing human monoclonal antibodies targeting prostate cancer cells in situ 有权
标题翻译：内源化靶向前列腺癌细胞的人单克隆抗体原位
公开(公告)号：US09593162B2
公开(公告)日：2017-03-14
申请号：US14486943
申请日：2014-09-15
申请人： The Regents of the University of California
发明人： Bin Liu , James D. Marks
IPC分类号： C07K16/30 , C07K16/18 , A61K51/10 , C07K16/28 , G01N33/574
CPC分类号： C07K16/3069 , A61K51/1072 , A61K2039/505 , C07K16/005 , C07K16/18 , C07K16/2803 , C07K16/30 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/569 , C07K2317/622 , C07K2317/77 , G01N33/5044 , G01N33/57434 , G01N33/6845 , G01N33/6854
摘要： This invention provides a method that allows selection of antibodies against cells (e.g., tumor cells) in situ using laser capture microdissection. By restricting antibody selection to binders of internalizing epitopes, a panel of phage antibodies was generated that targets clinically represented prostate cancer antigens.
摘要翻译：本发明提供允许使用激光捕获显微切割原位选择针对细胞（例如肿瘤细胞）的抗体的方法。通过将抗体选择限于内化表位的结合物，产生一组靶向临床表现的前列腺癌抗原的噬菌体抗体。

85. 发明申请

US20170067047A1 MICROFLUIDIC DEVICES AND METHODS OF USE IN THE FORMATION AND CONTROL OF NANOREACTORS 有权
标题翻译：微流体装置及其在纳米复合材料的形成与控制中的应用
公开(公告)号：US20170067047A1
公开(公告)日：2017-03-09
申请号：US15331452
申请日：2016-10-21
申请人： Raindance Technologies, Inc.
发明人： Darren Roy Link , Laurent Boitard , Jeffrey Branciforte , Yves Charles , Gilbert Feke , John Q. Lu , David Marran , Ahmadali Tabatabai , Michael Weiner , Wolfgang Hinz , Jonathan M. Rothberg
IPC分类号： C12N15/10
CPC分类号： C12N15/1075 , B01F3/0807 , B01F13/0071 , B01F13/0076 , B01J19/0046 , B01J2219/00286 , B01J2219/00459 , B01J2219/00466 , B01J2219/00468 , B01J2219/00479 , B01J2219/005 , B01J2219/00576 , B01J2219/00599 , B01J2219/00702 , B01J2219/0072 , B01J2219/00743 , B01L3/5027 , B01L3/502715 , B01L3/50273 , B01L3/502746 , B01L3/502761 , B01L3/502784 , B01L3/502792 , B01L3/565 , B01L7/52 , B01L2200/027 , B01L2200/0621 , B01L2200/0647 , B01L2200/0652 , B01L2200/0673 , B01L2300/0816 , B01L2300/0864 , B01L2300/0867 , B01L2300/0896 , B01L2400/0415 , B01L2400/0424 , B01L2400/0487 , B01L2400/084 , B82Y5/00 , B82Y30/00 , C07K1/047 , C12Q1/6804 , C12Q1/6816 , C12Q1/6825 , C12Q1/6834 , C12Q1/686 , C12Q1/6869 , C12Q1/6874 , C12Q1/6876 , C12Q2525/161 , C12Q2561/119 , C12Q2563/103 , C12Q2563/107 , C12Q2563/159 , C12Q2565/537 , C12Q2565/629 , C12Q2600/16 , C40B30/04 , C40B40/04 , C40B50/08 , C40B60/08 , C40B60/12 , C40B70/00 , G01N21/6428 , G01N21/6445 , G01N21/6458 , G01N33/536 , G01N33/542 , G01N33/543 , G01N33/6845 , G01N33/6854 , G01N2500/10
摘要： The present invention provides novel microfluidic devices and methods that are useful for performing high-throughput screening assays and combinatorial chemistry. The invention provides for aqueous based emulsions containing uniquely labeled cells, enzymes, nucleic acids, etc., wherein the emulsions further comprise primers, labels, probes, and other reactants. An oil based carrier-fluid envelopes the emulsion library on a microfluidic device, such that a continuous channel provides for flow of the immiscible fluids, to accomplish pooling, coalescing, mixing, sorting, detection, etc., of the emulsion library.
摘要翻译：本发明提供了可用于进行高通量筛选测定和组合化学的新型微流体装置和方法。本发明提供了含有唯一标记的细胞，酶，核酸等的含水基乳液，其中乳液还包含引物，标记，探针和其它反应物。油基载体流体在微流体装置上包封乳剂库，使得连续通道提供不混溶流体的流动，以实现乳液库的汇集，聚结，混合，分选，检测等。

86. 发明授权

US09588117B2 Detecting cells secreting a protein of interest 有权
标题翻译：检测分泌感兴趣的蛋白质的细胞
公开(公告)号：US09588117B2
公开(公告)日：2017-03-07
申请号：US14583351
申请日：2014-12-26
申请人： Berkeley Lights, Inc.
发明人： Kevin T. Chapman
IPC分类号： G01N33/569 , G01N33/68
CPC分类号： G01N33/56972 , G01N33/56911 , G01N33/56961 , G01N33/56966 , G01N33/6854 , G01N2458/00 , G01N2469/10
摘要： In some cases, the described systems and methods include obtaining a cell sample containing multiple antibody-producing cells. In such cases, the cells can be tagged with a cross-linking reagent having a first portion configured to bind to a marker on the antibody-producing cells and a second portion configured to bind to an antigen of interest. In some instances, the tagged antibody-producing cells are exposed to the antigen of interest such that the antigen becomes bound to the cells. In some such instances, the antibody-producing cells are also allowed to produce an antibody, such that a portion of the antibody-producing cells produce an antigen-specific antibody that binds to the antigen of interest. To identify cells that produce the antigen-specific antibody, the tagged cells can be exposed to a labeled secondary antibody that is configured to bind to the antigen-specific antibody. Other implementations are also described.
摘要翻译：在一些情况下，所描述的系统和方法包括获得含有多个产生抗体的细胞的细胞样品。在这种情况下，可以用交联试剂对细胞进行标记，所述交联试剂具有构建成结合抗体产生细胞上的标记的第一部分和被配置成与感兴趣的抗原结合的第二部分。在一些情况下，标记的产生抗体的细胞暴露于感兴趣的抗原，使得抗原与细胞结合。在一些这样的情况下，也允许产生抗体的细胞产生抗体，使得产生一部分抗体的细胞产生与感兴趣的抗原结合的抗原特异性抗体。为了鉴定产生抗原特异性抗体的细胞，标记的细胞可以暴露于被配置为结合抗原特异性抗体的标记的二抗。还描述了其他实现。

87. 发明授权

US09587013B2 Immunoaffinity isolation of modified peptides from complex mixtures 有权
标题翻译：来自复杂混合物的修饰肽的免疫亲和分离
公开(公告)号：US09587013B2
公开(公告)日：2017-03-07
申请号：US13868387
申请日：2013-04-23
申请人： Cell Signaling Technology, Inc.
发明人： John Rush , Hui Zhang , Xiangming Zha , Michael J Comb , Yi Tan
IPC分类号： G01N33/68 , C07K16/18 , B01D15/38 , C07K1/22 , C07K16/44 , G01N30/72 , G01N30/88
CPC分类号： C07K16/18 , B01D15/3809 , B01D15/3828 , C07K1/22 , C07K16/44 , G01N30/7233 , G01N33/6842 , G01N33/6848 , G01N33/6854 , G01N2030/8831 , G01N2440/14
摘要： The invention provides methods for isolating a modified peptide from a complex mixture of peptides, the method comprising the steps of: (a) obtaining a proteinaceous preparation from an organism, wherein the preparation comprises modified peptides from two or more different proteins; (b) contacting the preparation with at least one immobilized modification-specific antibody; and (c) isolating at least one modified peptide specifically bound by the immobilized modification-specific antibody in step (b). The method may further comprise the step of (d) characterizing the modified peptide isolated in step (c) by mass spectrometry (MS), tandem mass spectrometry (MS-MS), and/or MS3 analysis, or the step of (e) utilizing a search program to substantially match the spectra obtained for the modified peptide during the characterization of step (d) with the spectra for a known peptide sequence, thereby identifying the parent protein(s) of the modified peptide. Also provided are an immunoaffinity isolation device comprising a modification-specific antibody, and antibodies against novel UFD1 and PTN6 phosphorylation sites.
摘要翻译：本发明提供了从复杂的肽混合物中分离修饰的肽的方法，所述方法包括以下步骤：（a）从生物体获得蛋白质制剂，其中所述制剂包含来自两种或更多种不同蛋白质的修饰肽; （b）使制剂与至少一种固定的修饰特异性抗体接触; 和（c）在步骤（b）中分离至少一种由固定的修饰特异性抗体特异性结合的修饰的肽。该方法还可以包括以下步骤：（d）通过质谱（MS），串联质谱（MS-MS）和/或MS3分析表征步骤（c）中分离的修饰肽，或（e）利用搜索程序将在步骤（d）表征期间获得的修饰肽的光谱与已知肽序列的光谱基本上匹配，从而鉴定修饰肽的亲本蛋白。还提供了包含修饰特异性抗体和针对新型UFD1和PTN6磷酸化位点的抗体的免疫亲和分离装置。

88. 发明申请

US20170051069A1 ANTI-CD134 (OX40) ANTIBODIES AND USES THEREOF 审中-公开
标题翻译：抗-CD134（OX40）抗体及其用途
公开(公告)号：US20170051069A1
公开(公告)日：2017-02-23
申请号：US15247425
申请日：2016-08-25
申请人： Biocerox Products B.V. , Janssen Pharmaceuticals, Inc.
发明人： Petrus Johannes Simons , Louis Boon
IPC分类号： C07K16/28 , C07K16/30
CPC分类号： C07K16/2878 , C07K16/30 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/74 , G01N33/6854 , G01N2333/705
摘要： The invention provides antibodies that specifically bind to human CD134. Invention anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 lymphocytes (Tregs). Invention anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
摘要翻译：本发明提供特异性结合人CD134的抗体。本发明的抗人CD134抗体特异性结合人CD134的细胞外结构域，包括人CD134上的非OX40配体（OX40L）结合结构域，其在例如，活化的人常规效应器CD4和/或CD8 T淋巴细胞（Teffs）和活化的人抑制性调节性CD4淋巴细胞（Treg）。本发明的抗人CD134抗体可用于癌症治疗（例如赋予Teffs抗癌效应子功能和/或抑制Tregs抑制功能）。

89. 发明申请

US20170045511A1 ASSAYS AND METHODS FOR THE DIAGNOSIS OF POST-STREPTOCOCCAL DISORDERS 审中-公开
标题翻译：诊断后结膜疾病的方法和方法
公开(公告)号：US20170045511A1
公开(公告)日：2017-02-16
申请号：US15157949
申请日：2016-05-18
申请人： Quest Diagnostics Investments Incorporated
发明人： Stanley J. Naides , Joanna Popov
IPC分类号： G01N33/564 , G01N33/569
CPC分类号： G01N33/564 , G01N33/56944 , G01N33/6854 , G01N2333/315 , G01N2469/20 , G01N2800/38
摘要： Provided are methods for diagnosing a disease in a subject with a previous streptococcal infection by determining the presence or absence of one or more autoantibodies in a biological sample from the subject, wherein the one or more autoantibodies recognize an antigen from a protein selected from the group consisting of ELAVL2, ELAVL3, ELAVL4, Nova-1, Nova-2, Cdr1, Cdr2; and Cdr3. The presence of such autoantibodies is indicative of a positive diagosis for a post-streptococcal disease such as PANDAS, post-GABHS glomerulonephritis, rheumatic fever, autism and Syndenham's chorea.
摘要翻译：提供了通过确定来自受试者的生物样品中是否存在一种或多种自身抗体来诊断患有先前的链球菌感染的受试者的疾病的方法，其中所述一种或多种自身抗体识别来自选自组中的蛋白质的抗原由ELAVL2，ELAVL3，ELAVL4，Nova-1，Nova-2，Cdr1，Cdr2组成; 和Cdr3。这种自身抗体的存在表明了后链球菌疾病如PANDAS，GABHS后肾小球性肾炎，风湿热，自闭症和Syndenham舞蹈病之间的阳性诊断。

90. 发明申请

US20170044523A1 METHOD FOR RECOVERING TWO OR MORE GENES, OR GENE PRODUCTS, ENCODING AN IMMUNORECEPTOR 审中-公开
标题翻译：用于恢复两种或多种基因或基因产物的方法，编码免疫球蛋白
公开(公告)号：US20170044523A1
公开(公告)日：2017-02-16
申请号：US15118676
申请日：2015-02-13
申请人： MEMO THERAPEUTICS AG
发明人： Martin HELD , Christoph ESSLINGER
IPC分类号： C12N15/10
CPC分类号： C12N15/1082 , C07K16/00 , C07K16/005 , C12Q1/6806 , C12Q1/686 , G01N33/5023 , G01N33/5047 , G01N33/6845 , G01N33/6854 , C12Q2521/107 , C12Q2563/149 , C12Q2563/159
摘要： The present invention is related to a method for recovering two or more genes, or gene products, or cDNAs, encoding for an immunoreceptor having two or more subunits, which two or more genes, or gene products, are comprised in a given source cell. The invention is further related to a method of creating a library of expressor cells, in which library each cell is capable of expressing two or more genes, or gene products, encoding for the subunits of the immunoreceptor. The invention is further related to a method of screening a library of expressor cells as created according to the above method, for one cell that expresses an immunoreceptor that has specificity for a given target molecule.
摘要翻译：本发明涉及一种用于回收编码具有两个或多个亚基的免疫受体的两个或多个基因或基因产物或cDNA的方法，所述两个或多个基因或基因产物包含在给定的源细胞中。本发明还涉及创建表达细胞文库的方法，其中文库每个细胞能够表达编码免疫受体亚单位的两个或多个基因或基因产物。本发明进一步涉及对于表达对给定靶分子具有特异性的免疫受体的一个细胞，筛选根据上述方法产生的表达细胞文库的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式